
MANNKIND CORP
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
MannKind Corporation develops and commercializes inhaled therapies for diabetes and other endocrine and orphan lung diseases, including Afrezza, an inhaled rapid-acting insulin taken at mealtime.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Binder Steven B.Insider | Sell | $128K | 33,558at $3.81 | Sep 10, 2026 |
| Binder Steven B.Insider | Sell | $159K | 39,051at $4.06 | Aug 7, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable MNKD activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.